ReviewBMC medicine2012
State of progress in treating cystic fibrosis respiratory disease.
Review in BMC medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Impact on Body Composition After Two Years of Elexacaftor-Tezacaftor-Ivacaftor Therapy in Children with Cystic Fibrosis.Children (Basel, Switzerland) · 2025Article
- Use of mucoactive agents in cystic fibrosis: A consensus survey of Italian specialists.Health science reports · 2022Review
- LipNanoCar Technology - A Versatile and Scalable Technology for the Production of Lipid Nanoparticles.Advances in experimental medicine and biology · 2022Article
- Identification of novel targets of azithromycin activity againstProceedings of the National Academy of Sciences of the United States of America · 2020Article
- Inhaled dry powder alginate oligosaccharide in cystic fibrosis: a randomised, double-blind, placebo-controlled, crossover phase 2b study.ERJ open research · 2020Article
- Article
- Replication of the Ordered, Nonredundant Library of Pseudomonas aeruginosa strain PA14 Transposon Insertion Mutants.Journal of visualized experiments : JoVE · 2018Article
- Cystic Fibrosis and the Nervous System.Chest · 2017Review
- Immunonutrition in patients with cyctic fibrosis leads to drop of serum amyloid A and increase of oxidative stress.Journal of clinical biochemistry and nutrition · 2017Article
- Attitudes Toward Discussing Approved and Investigational Treatments for Cystic Fibrosis in Prenatal Genetic Counseling Practice.Journal of genetic counseling · 2017Article
- Review
- Activity of Cysteamine against the Cystic Fibrosis Pathogen Burkholderia cepacia Complex.Antimicrobial agents and chemotherapy · 2016Article
- Review
- Ventilatory abnormalities in patients with cystic fibrosis undergoing the submaximal treadmill exercise test.BMC pulmonary medicine · 2015Article
- Cystic Fibrosis Treatment: A Paradigm for New Pediatric Medicines, Globalization of Drug Development and the Role of the European Medicines Agency.Children (Basel, Switzerland) · 2015Review
- [Cystic fibrosis and associated complications].Der Internist · 2015Article
- Free DNA in cystic fibrosis airway fluids correlates with airflow obstruction.Mediators of inflammation · 2015Article
- Direct interactions between ENaC gamma subunit and ClCN2 in cystic fibrosis epithelial cells.Physiological reports · 2015Article
- Pathophysiology of cystic fibrosis and drugs used in associated digestive tract diseases.World journal of gastroenterology · 2013Review
- Nanotechnology approaches for inhalation treatment of fibrosis.Journal of drug targeting · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the discovery of the gene associated with cystic fibrosis (CF), there has been tremendous progress in the care of patients with this disease. New therapies have entered the market and are part of the standard treatment of patients with CF, and have been associated with marked improvement in survival. Now there are even more promising therapies directed at different components of the pathophysiology of this disease. In this review, our current knowledge of the pathophysiology of lung disease in patients with CF is described, along with the current treatment of CF lung disease, and the therapies in development that offer great promise to our patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.